Literature DB >> 19673855

Outlining ethical issues in nanotechnologies.

Antonio G Spagnolo1, Viviana Daloiso.   

Abstract

Nanotechnologies are an expression of the human ability to control and manipulate matter on a very small scale. Their use will enable an even and constant monitoring of human organisms, in a new and perhaps less invasive way. Debates at all levels--national, European and international--have pointed out the common difficulty of giving a complete, clear definition of nanotechnologies. This is primarily due to the variety of their components, to the fact that there is not just one technology but several. The most significant medical applications of nanotechnologies are in the diagnostic and the therapeutic fields, eg biosensors and molecular imaging, providing diagnosis and drug delivery with no invasive methods involved. Like any other emerging field, such technologies imply new possibilities for improving health but, on the other hand, they are still at an experimental stage and therefore should be implemented under rigorous safety testing before going on general release. For this purpose, the ethical, legal and social implications (ELSI) of nanotechnologies have been elaborated by study groups, in order to develop solutions before the results of the tests are diffused into medical practice. The aim of this paper is to define some of the ethical issues concerning biomedical applications and to evaluate whether there is a need for new or additional guidelines and regulations.

Entities:  

Mesh:

Year:  2009        PMID: 19673855     DOI: 10.1111/j.1467-8519.2007.00623.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  6 in total

Review 1.  Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19.

Authors:  Nikhil Bhalla; Yuwei Pan; Zhugen Yang; Amir Farokh Payam
Journal:  ACS Nano       Date:  2020-06-26       Impact factor: 15.881

Review 2.  Chronopharmaceutical drug delivery systems: Hurdles, hype or hope?

Authors:  Bi-Botti C Youan
Journal:  Adv Drug Deliv Rev       Date:  2010-05-12       Impact factor: 15.470

3.  Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field.

Authors:  Leili Fatehi; Susan M Wolf; Jeffrey McCullough; Ralph Hall; Frances Lawrenz; Jeffrey P Kahn; Cortney Jones; Stephen A Campbell; Rebecca S Dresser; Arthur G Erdman; Christy L Haynes; Robert A Hoerr; Linda F Hogle; Moira A Keane; George Khushf; Nancy M P King; Efrosini Kokkoli; Gary Marchant; Andrew D Maynard; Martin Philbert; Gurumurthy Ramachandran; Ronald A Siegel; Samuel Wickline
Journal:  J Law Med Ethics       Date:  2012       Impact factor: 1.718

4.  Building an ethical foundation for first-in-human nanotrials.

Authors:  Rebecca Dresser
Journal:  J Law Med Ethics       Date:  2012       Impact factor: 1.718

5.  Ethics and Nanopharmacy: Value Sensitive Design of New Drugs.

Authors:  Job Timmermans; Yinghuan Zhao; Jeroen van den Hoven
Journal:  Nanoethics       Date:  2011-11-09       Impact factor: 0.917

6.  Ethical analysis in HTA of complex health interventions.

Authors:  Kristin Bakke Lysdahl; Wija Oortwijn; Gert Jan van der Wilt; Pietro Refolo; Dario Sacchini; Kati Mozygemba; Ansgar Gerhardus; Louise Brereton; Bjørn Hofmann
Journal:  BMC Med Ethics       Date:  2016-03-22       Impact factor: 2.652

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.